Navigation Links
Strativa Pharmaceuticals Acquires Worldwide Rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray From QOL Medical

First and Only Once-weekly, Self-administered Alternative to Injections for Treatment of Vitamin B12 Deficiency

WOODCLIFF LAKE, N.J., April 1 /PRNewswire-FirstCall/ -- Strativa Pharmaceuticals, the proprietary products division of a wholly owned subsidiary of Par Pharmaceutical Companies, Inc. (NYSE: PRX), today announced it has acquired the worldwide rights to Nascobal(R) (Cyanocobalamin, USP) Nasal Spray from QOL Medical LLC. Nascobal Nasal Spray is an FDA approved prescription vitamin B12 supplement indicated to treat vitamin B12 deficiency. It is the first and only once-weekly, self-administered alternative to B12 injections.

Under the terms of the all cash transaction, Strativa Pharmaceuticals will pay QOL Medical $54.5 million for the worldwide rights to Nascobal Nasal Spray. Revenues of Nascobal exceeded $8.0 million in 2008. Nascobal Nasal Spray will be manufactured by Par, which also acquired the MDRNA (formerly Nastech) facility where the product is manufactured.

"The acquisition of Nascobal Nasal Spray represents an important milestone in the execution of our corporate strategy to accelerate the growth of Strativa," said Patrick G. LePore, Chairman, Chief Executive Officer and President of Par. "The addition of Nascobal to our current portfolio, coupled with our promising product pipeline, well positions Strativa within the U.S. specialty pharmaceutical industry."

Millions of Americans are treated for vitamin B12 deficiency. The leading causes of vitamin B12 deficiency include pernicious anemia, a strict vegetarian diet, malabsorption of vitamin B12 resulting from conditions such as HIV infection, AIDS, Crohn's disease, multiple sclerosis and partial or total gastrectomy, among others. In 2008, more than 45 million vitamin B12 injections were prescribed to patients in the United States.

John A. MacPhee, President of Strativa Pharmaceuticals, said, "We believe that Nascobal Nasal Spray offers important benefits to people with a vitamin B12 deficiency. Given the large size of the prescription vitamin B12 market and Strativa's sales and marketing expertise, we believe that Nascobal is poised for significant growth."

Nascobal Nasal Spray, approved by the U.S. Food and Drug Administration in 2005, contains a synthetic form of vitamin B12 that is readily absorbed into the bloodstream through the nose and provides steady serum levels without the need for monthly injections received at the physician's office. Nascobal Nasal Spray's once-weekly dosing is convenient for patients and can minimize peaks and troughs in B12 serum levels that may be associated with monthly injections.

Nascobal Nasal Spray Safety Information

Nascobal(R) Nasal Spray is indicated for the maintenance of normal hematologic status in pernicious anemia patients who are in remission following intramuscular vitamin B12 therapy and who have no nervous system involvement. Nascobal Nasal Spray is also indicated as a supplement for other vitamin B12 deficiencies including: dietary deficiency of vitamin B12 occurring in strict vegetarian diets; malabsorption of vitamin B12 resulting from conditions including HIV infection, AIDS, and Crohn's disease; inadequate secretion of intrinsic factor resulting from lesions that destroy the gastric mucosa and other conditions associated with gastric atrophy including multiple sclerosis, HIV infection, AIDS, certain endocrine disorders, iron deficiency, and subtotal gastrectomy; total gastrectomy; competition for vitamin B12 by intestinal parasites or bacteria; and inadequate utilization of vitamin B12 that may occur if antimetabolites for the vitamin are employed in the treatment of neoplasia.

Nascobal Nasal Spray is contraindicated in patients with sensitivity to cobalt and/or vitamin B12 or any component of the medication. If a patient is not properly maintained with Nascobal Nasal Spray, intramuscular vitamin B12 is necessary. Vitamin B12 concentrations must be monitored.

Patients with pernicious anemia should be instructed that they will require weekly administration of Nascobal Nasal Spray for the remainder of their lives. Failure to do so will result in return of the anemia and in development of incapacitating and irreversible damage to the nerves of the spinal cord. Hypokalemia and sudden death may occur in severe megaloblastic anemia which is treated intensely with vitamin B12.

Side effects thought to be related to Nascobal use are usually mild and include headache, nausea and rhinitis.

Please see full prescribing information.

About Strativa Pharmaceuticals

Strativa Pharmaceuticals is the proprietary products division of Par Pharmaceutical, Inc. Strativa is committed to developing and marketing novel prescription drugs. Its initial focus is on supportive care therapeutics in HIV and oncology. Drawing on the specialty products expertise of its staff, Strativa possesses the resources to prepare products for commercialization and to help ensure their success after launch. For additional information, please visit

About Par Pharmaceutical

Par Pharmaceutical, Inc. develops, manufactures and markets generic drugs and innovative branded pharmaceuticals for specialty markets. For press release and other company information, visit

Safe Harbor Statement

Certain statements in this news release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. To the extent any statements made in this news release contain information that is not historical, these statements are essentially forward-looking and, as such, are subject to known and unknown risks, uncertainties and contingencies, many of which are beyond the control of the Company, which could cause actual results and outcomes to differ materially from those expressed herein. Risk factors that might affect such forward-looking statements include those set forth in Item 1A of the Company's Annual Report on Form 10-K for the year ended December 31, 2008, in other of the Company's filings with the SEC from time to time, including Current Reports on Form 8-K, and on general industry and economic conditions. Any forward-looking statements included in this news release are made as of the date hereof only, based on information available to the Company as of the date hereof, and, subject to any applicable law to the contrary, the Company assumes no obligation to update any forward-looking statements.

SOURCE Par Pharmaceutical, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Strativa Pharmaceuticals Acquires Commercialization Rights to Thin Film Formulation of Ondansetron From MonoSol Rx
2. MonoSol Rx Licenses Thin Film Formulation of Ondansetron to Strativa Pharmaceuticals, a Division of Par Pharmaceutical
3. Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders
4. Arena Pharmaceuticals Announces Positive Lorcaserin Pivotal Phase 3 Obesity Trial Results: Meets All Primary Efficacy and Safety Endpoints
5. Zydus Pharmaceuticals (USA) Inc. Announces FDA Final Approval for the Generic Version of Topamax(R) Tablets
6. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2008 Financial Results
7. Meeting to examine FDA requirements for manufacturing PET radiopharmaceuticals
8. Sagent Pharmaceuticals Announces U.S. FDA Approval of Azithromycin for Injection
9. Celator(R) Pharmaceuticals to Present at Future Leaders in the Biotech Industry Conference
10. Anadys Pharmaceuticals to Present at the Citi Biotech Day
11. Endo Pharmaceuticals Solutions (Formerly Indevus Pharmaceuticals, Inc.) Announces Commencement of Offer to Purchase Its 6.25% Convertible Senior Notes Due 2009
Post Your Comments:
(Date:11/27/2015)... ... 2015 , ... Keeping in mind challenges faced by parents ... consultation, has collaborated with a leading web-based marketplace for extra-curricular activities for children ... and bring advice from parenting experts within their reach. As a part of ...
(Date:11/27/2015)... ... November 27, 2015 , ... The men and women ... healthcare organizations in the country. They have overseen financial turnarounds, shown commitment to ... the healthcare industry as a whole through their advocacy and professional efforts. , ...
(Date:11/27/2015)... ... November 27, 2015 , ... Avid collector, Andrew Hawley from Vintage ... style concert posters. This is one of Joplin's most famous and beautiful concert posters. ... University of Michigan in Ann Arbor. The According to Hawley, "It is hard to ...
(Date:11/26/2015)... ... November 26, 2015 , ... Patients at Serenity ... have come together on Thanksgiving Day to share the things that they are ... the Serenity Point YouTube channel, patients displayed what they wrote on index cards, ...
(Date:11/26/2015)... ON and Cambridge, ON (PRWEB) , ... November ... ... today the availability of a real-time eReferral system for diagnostic imaging in the ... ultrasounds, X-rays, mammography, BMD and Nuclear Medicine tests directly from their electronic medical ...
Breaking Medicine News(10 mins):
(Date:11/27/2015)... , Nov. 27, 2015  Lannett Company, ... it has completed the acquisition of Kremers Urban ... subsidiary of global biopharmaceuticals company UCB S.A. (Euronext: ... Lannett has acquired KU from UCB for ... certain adjustments, including a customary working capital adjustment, ...
(Date:11/26/2015)... , 26 november 2015 ... kondigt de geplande investering aan van ten ... de laboratoria en het mondiale hoofdkantoor in ... uitbreiding zal resulteren in extra kantoorruimte en ... aan de groeiende behoeften van de farmaceutische ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
Breaking Medicine Technology: